HC Wainwright & Co. Reiterates Buy on KalVista Pharma, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for KalVista Pharma, maintaining a price target of $20. This suggests confidence in the company's future performance.
September 06, 2024 | 11:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for KalVista Pharma, maintaining a price target of $20. This suggests confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $20 price target by HC Wainwright & Co. indicates a positive outlook for KalVista Pharma. This can lead to increased investor confidence and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100